Implantable “drug factories” that kill advanced-stage ovarian and colorectal cancer in mice in six day could be ready for human clinical trials this fall.
Category: biotech/medical – Page 1211
Nash and Veiseh with vials of bead-like “drug factories” they created to treat cancer. The beads are designed to continuously produce natural compounds that program the immune system to attack tumors. (Credit: Jeff Fitlow/Rice)
The therapy could be ready for human clinical trials later this year.
Can we turn up—or dial down—their fervor by tweaking their genes?
Enter a new kind of CRISPR. Known mostly as a multi-tool to cut, snip, edit, or otherwise kneecap an existing gene, this version—dubbed CRISPRa—forcibly turns genes on. Optimized by scientists at Gladstone Institutes and UC San Francisco, the tool is counterbalanced by CRISPRi—“i” for “interference,” which, you guessed it, interferes with the gene’s expression.
Though previously used in immortal cells grown in labs, this is the first time these CRISPR tools are rejiggered for cells extracted from our bodies. Together, the tools simultaneously screened nearly 20,000 genes in T cells isolated from humans, building a massive genetic translator—from genes to function—that maps how individual genes influence T cells.
Researchers at the Stanford University School of Medicine say that they were able to treat depression in patients by stimulating their brains with magnets.
In a study published on Friday 0, the researchers found that nearly 80 percent of patients had experienced remission of their depression after the procedure, which is called Stanford neuromodulation therapy (SNT). The technique is a modified form of transcranial magnetic stimulation (rTMS) and works by delivering high doses of magnetic pulses into a patient’s brain with a device containing magnetic coils placed outside of their skull.
The treatment takes just five days and is customized to each patient based on an MRI scan which shortens the typical timeline of rTMS treatment from a span of weeks into days.
In a pilot human study, researchers from the University of Minnesota Medical School and Massachusetts General Hospital show it is possible to improve specific human brain functions related to self-control and mental flexibility by merging artificial intelligence with targeted electrical brain stimulation.
Alik Widge, MD, Ph.D., an assistant professor of psychiatry and member of the Medical Discovery Team on Addiction at the U of M Medical School, is the senior author of the research published in Nature Biomedical Engineering. The findings come from a human study conducted at Massachusetts General Hospital in Boston among 12 patients undergoing brain surgery for epilepsy—a procedure that places hundreds of tiny electrodes throughout the brain to record its activity and identify where seizures originate.
In this study, Widge collaborated with Massachusetts General Hospital’s Sydney Cash, MD, Ph.D., an expert in epilepsy research; and Darin Dougherty, MD, an expert in clinical brain stimulation. Together, they identified a brain region—the internal capsule—that improved patients’ mental function when stimulated with small amounts of electrical energy. That part of the brain is responsible for cognitive control—the process of shifting from one thought pattern or behavior to another, which is impaired in most mental illnesses.
Scientists at Shanghai Jiao Tong University altered a mouse’s DNA to impregnate it through asexual reproduction.
A redesigned Cas9 is thousands of times less likely to target the wrong stretch of DNA while remaining just as efficient as the original version.
Researchers at NTNU have managed to restore muscle function in older mice with muscle loss using advanced gene therapy. The hope is that this method might eventually be used on humans to prevent severe loss of muscle mass.
“Gene therapy is the most effective method to be able to give these people the same health benefits you normally get with physical exercise,” says Moreira, who has been involved in the new research. He is part of the Cardiac Exercise Research Group (CERG).
With age comes experience. And with experience come sore backs, tired bones, and increased risks from a large number of diseases.
Scientists have long been trying figure out how to stop these aches and pains in our twilight years, and to make us live longer and healthier lives at the same time.
While it’s likely a long way off from being ready for humans, a new study investigating the long-term ‘partial reprogramming’ of cells in mice appears to have produced some very intriguing results.
Adult cells in our body can only give rise to the same cell type. For example, a skin cell cannot give rise to a muscle cell but to skin cells only. This limits the potential use of adult cells for therapy. During early development, however, the cells in the embryo have the capacity to generate all cell types of our body, including stem cells. This capacity, which is called totipotency, has served as an inspiration for researchers to find new ways to recapitulate totipotency through cellular reprogramming in the lab.
Totipotent cells have their own speed
Totipotent cells have many properties, but we do not know all of them yet. Researchers at Helmholtz Munich have now made a new discovery: “We found out that in totipotent cells, the mother cells of stem cells, DNA replication occurs at a different pace compared to other more differentiated cells. It is much slower than in any other cell type we studied,” says Tsunetoshi Nakatani, first-author of the new study.